Heart Failure

Heart failure is one of the great paradoxes of medicine: it is not that the heart has stopped, but that the heart can no longer keep up. The pump is still beating — often faster and harder than ever — yet it cannot deliver enough oxygenated blood to meet the body's demands, or it can only do so at the cost of dangerously high filling pressures that back up into the lungs and body. Understanding heart failure means understanding the heart not as a simple pump, but as an organ embedded in a web of reflexes, hormones, and pressures that were designed to protect us in the short term and that slowly destroy the heart over the long term.

This is a syndrome you will meet constantly — in the emergency department at 3 a.m. with a patient drowning in their own pulmonary edema, in clinic managing the fine balance of five different drugs, and on the wards watching a chronic disease that now affects tens of millions worldwide. Master the physiology here and the treatment logic falls into place beautifully, because nearly every modern drug targets a specific piece of the machinery you are about to learn.

Learning Objectives

• Define heart failure as a clinical syndrome and distinguish it from cardiac arrest and from asymptomatic cardiac dysfunction.
• Differentiate systolic failure (HFrEF) from diastolic failure (HFpEF) by mechanism, ejection fraction, and typical patient.
• Explain preload, afterload, and contractility, and use the Frank-Starling law to reason about compensation and decompensation.
• Recognise the symptoms and signs of left- versus right-sided failure.
• Trace the neurohormonal cascade (RAAS and sympathetic activation) and explain why it is both compensatory and harmful.
• Justify each pillar of modern therapy on mechanistic grounds, from Withering's digitalis to the four-drug "quadruple therapy."

Quick Answer

Heart failure is a clinical syndrome in which the heart cannot pump enough blood to meet the body's metabolic needs at normal filling pressures. It is classified by ejection fraction into HFrEF (reduced, ≤40%, a problem of contraction/systole) and HFpEF (preserved, ≥50%, a problem of relaxation/filling in diastole). The failing heart triggers compensatory neurohormonal responses — sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) — that raise preload and afterload, initially maintaining output but ultimately accelerating cardiac damage. Symptoms come from congestion (breathlessness, oedema) and from low output (fatigue, poor perfusion). The Frank-Starling law explains how stretching cardiac muscle increases force, and how a failing heart operates on a flattened curve. Treatment has evolved from symptom relief (digitalis, diuretics) to blocking the harmful neurohormonal cascade, which is what genuinely prolongs life.

Where It Came From

For most of medical history, the swollen legs, breathlessness, and "dropsy" (generalised fluid accumulation) of heart failure were treated with folk remedies, bloodletting, and desperation. The turning point came in 1785, when the English physician William Withering published An Account of the Foxglove and Some of Its Medical Uses. Withering had learned of an old Shropshire woman's herbal cure for dropsy, tested its many ingredients, and identified the active one: the foxglove plant (Digitalis purpurea). Withering carefully worked out dosing and toxicity — remarkably scientific for his era — and gave cardiology its first genuinely effective drug. Digitalis increases the force of contraction and, we now know, also blunts harmful reflex signalling.

The next two centuries added tools but not deep understanding. Diuretics — first mercurials, then the game-changing thiazides (1950s) and loop diuretics (furosemide, 1960s) — could drain the congested lungs and legs. The prevailing model was simple and mechanical: the heart is a weak pump, so squeeze it harder (digitalis, later dobutamine) and drain the excess fluid (diuretics). This "cardiorenal" and then "hemodynamic" model dominated care.

The revolution came when physiologists realised that heart failure is not merely a plumbing problem but a neurohormonal disease. The body, sensing low output, activates the same systems it uses for haemorrhage — sympathetic drive and RAAS — flooding the circulation with noradrenaline, angiotensin II, and aldosterone. These raise blood pressure and retain salt and water in the short term, but chronically they cause vasoconstriction, fibrosis, arrhythmia, and direct toxicity to heart muscle (adverse remodelling). The landmark CONSENSUS trial (1987) showed that the ACE inhibitor enalapril reduced mortality — the first proof that blocking this cascade, rather than just stimulating the pump, saved lives. Counterintuitively, beta-blockers — long forbidden in heart failure because they weaken contraction — were shown in the 1990s (CIBIS-II, MERIT-HF) to dramatically reduce death by protecting the heart from chronic adrenergic assault. This neurohormonal paradigm still governs everything we do today.

Systolic vs Diastolic Failure: Two Ways to Fail

The heart must both contract to eject blood (systole) and relax to fill with blood (diastole). Failure of either produces the same downstream congestion but demands very different reasoning.

Heart failure with reduced ejection fraction (HFrEF) — classic systolic failure. The ventricle is weak; it cannot squeeze out an adequate fraction of the blood it holds. The ejection fraction (EF) — the percentage of end-diastolic volume ejected per beat — falls to 40% or below (normal is roughly 55–70%). The ventricle typically dilates (eccentric hypertrophy), becoming a large, floppy, thin-walled chamber. Common causes: ischaemic heart disease/prior myocardial infarction (the leading cause), dilated cardiomyopathy, and long-standing valvular disease.

Heart failure with preserved ejection fraction (HFpEF) — diastolic failure. Here the ventricle contracts normally (EF ≥50%) but is stiff and cannot relax and fill properly. A small, thick-walled, non-compliant chamber needs high filling pressures to admit a normal volume of blood — and those high pressures back up into the lungs. Because the chamber empties well but never filled well, stroke volume still falls. Typical patient: older, often female, with hypertension, obesity, diabetes, and atrial fibrillation. HFpEF now accounts for roughly half of all heart failure and, frustratingly, responded poorly to the drugs that transformed HFrEF — until SGLT2 inhibitors.

A middle category, HFmrEF (mildly reduced, EF 41–49%), is now recognised and generally managed like HFrEF.

Feature	HFrEF (systolic)	HFpEF (diastolic)
Ejection fraction	40% or below	50% or above
Core defect	Weak contraction	Impaired relaxation/filling
Ventricle	Dilated, thin-walled	Stiff, thick-walled
Typical cause	Prior MI, cardiomyopathy	Hypertension, obesity, diabetes, AF
Proven mortality drugs	ACEi/ARNI, beta-blocker, MRA, SGLT2i	SGLT2 inhibitors (main proven benefit)

Preload, Afterload, and Contractility

Three levers determine how much blood the heart pumps each minute (cardiac output = stroke volume × heart rate).

• Preload is the degree of ventricular stretch at end-diastole — essentially the volume of blood filling the ventricle before it contracts. It rises with fluid overload, salt retention, and venous return. Think of it as "how full the chamber is before the squeeze."
• Afterload is the resistance the ventricle must overcome to eject blood — dominated by arterial blood pressure and systemic vascular resistance. Think of it as "how hard the door is to push open." A hypertensive, vasoconstricted patient has high afterload, and a failing ventricle is exquisitely sensitive to it: raise afterload and stroke volume drops.
• Contractility (inotropy) is the intrinsic force of contraction independent of preload and afterload. It is reduced in HFrEF.

This framework explains treatment at a glance. Diuretics and nitrates reduce preload (relieving congestion). ACE inhibitors, ARBs, and hydralazine reduce afterload (making it easier for the weak ventricle to eject). Digoxin and dobutamine raise contractility. A single mnemonic — reduce preload, reduce afterload, support contractility — organises most of acute management.

The Frank-Starling Law: The Heart's Built-in Compensation

In the early 1900s, Otto Frank and Ernest Starling established one of physiology's most elegant principles: within limits, the more the cardiac muscle is stretched during filling, the more forcefully it contracts. Mechanistically, greater stretch optimises the overlap of actin and myosin filaments and increases the sensitivity of the contractile proteins to calcium. The practical consequence: if venous return rises, the ventricle fills more, stretches more, and automatically pumps out more — beat by beat, the heart matches its output to what returns to it, without any external signal.

Plot stroke volume against preload and you get the Frank-Starling curve — rising steeply then plateauing. This is central to understanding heart failure:

• A normal heart sits on a high, steep curve.
• A failing heart operates on a lower, flatter curve. For any given preload, it produces less stroke volume.
• To compensate, the failing heart moves rightward along its curve — retaining fluid to raise preload and squeeze out more volume. This is the body's short-term rescue.
• But push preload too far and you reach the flat top: extra filling yields no extra output and instead just raises pressures, which back up into the lungs → pulmonary congestion and oedema. The patient is now "wet" without any gain in output.

This is exactly why a diuretic can make a congested patient feel dramatically better without weakening the heart: you are sliding them back down off the overloaded flat portion of the curve, dropping the filling pressure that was flooding their lungs, at little or no cost to output.

Worked example. A man with HFrEF arrives breathless, with crackles to mid-lung and pitting oedema. His high preload has pushed him onto the flat, congested end of his depressed Starling curve. IV furosemide offloads several litres of fluid: preload falls, filling pressures drop, the lungs clear, and he breathes easily — yet his stroke volume barely changes, because on the flat part of the curve, less filling costs almost no output. Meanwhile, starting an ACE inhibitor lowers his afterload, shifting him onto a slightly higher curve so that over weeks his output improves too.

The Neurohormonal Cascade: A Compensation That Becomes the Disease

When cardiac output falls, the body cannot tell the difference between heart failure and blood loss — so it activates the same emergency responses.

1. Sympathetic activation. Baroreceptors sense low output and unleash noradrenaline: heart rate rises, contractility rises, and arteries constrict. Helpful for an afternoon; toxic for years. Chronic catecholamine exposure causes myocyte death, downregulation of beta-receptors, arrhythmias, and remodelling.
2. RAAS activation. Reduced renal perfusion triggers renin release → angiotensin II (a potent vasoconstrictor that raises afterload) → aldosterone (retains salt and water, raising preload). Angiotensin II and aldosterone also drive fibrosis of the heart and vessels — the structural scarring that stiffens and enlarges the failing ventricle.

The result is a vicious cycle: falling output → neurohormonal activation → increased preload, afterload, and remodelling → further decline in output. Breaking this cycle is the entire basis of life-prolonging therapy. Every mortality-reducing drug in HFrEF acts here.

Symptoms and Signs

Heart failure symptoms flow logically from where the blood backs up and from low forward output.

Left-sided failure → pulmonary congestion:

• Dyspnoea on exertion, then at rest.
• Orthopnoea — breathlessness lying flat (fluid redistributes to the lungs); patients sleep propped on pillows.
• Paroxysmal nocturnal dyspnoea (PND) — waking gasping for air 1–2 hours into sleep.
• Fine bibasal crackles, and in severe cases pink frothy sputum from pulmonary oedema.

Right-sided failure → systemic congestion:

• Peripheral (pitting) oedema, ankles and sacrum.
• Raised jugular venous pressure (JVP) — the most useful bedside sign of volume status.
• Hepatomegaly and ascites; the most common cause of right heart failure is left heart failure (together, congestive cardiac failure).

Low output: fatigue, exercise intolerance, cool peripheries, and, when severe, confusion and hypotension (cardiogenic shock).

The New York Heart Association (NYHA) classes I–IV grade functional limitation — from no limitation (I) to symptoms at rest (IV) — and guide both prognosis and therapy intensity. Investigations centre on BNP/NT-proBNP (natriuretic peptides released by stretched ventricles; a normal level makes heart failure unlikely) and echocardiography (which measures EF and separates HFrEF from HFpEF).

Real-World Applications

• Emergency medicine. Acute pulmonary oedema is a true emergency. The immediate approach — sit the patient up, high-flow oxygen or non-invasive ventilation (CPAP), IV loop diuretic, and nitrates to slash preload and afterload — is a direct application of the preload/afterload framework.
• Chronic clinic management. Titrating quadruple therapy to target doses, monitoring renal function and potassium (RAAS drugs raise potassium; diuretics lower it), and tracking daily weights so patients catch fluid gain early.
• Everyday self-management. Salt and fluid restriction, daily weighing (a gain of 2 kg over a few days signals fluid retention), medication adherence, and cardiac rehabilitation all measurably reduce hospital readmission.
• Device therapy. Selected patients benefit from an ICD (to prevent sudden arrhythmic death) or cardiac resynchronisation therapy (CRT) to coordinate a dyssynchronous ventricle — physiology translated into hardware.

Common Mistakes

1. "Heart failure means the heart has stopped." Wrong — that is cardiac arrest. In heart failure the heart is still beating, often working overtime; the problem is inadequate output relative to demand, or adequate output only at the price of high congestive pressures.
2. "A normal ejection fraction rules out heart failure." Wrong, and dangerous. Half of all heart failure is HFpEF, where EF is preserved but the stiff ventricle fails to fill. You must consider diastolic failure in the breathless, hypertensive, oedematous older patient with a "normal" echo EF.
3. "Beta-blockers are contraindicated because they weaken the heart." This was believed for decades and is exactly backwards for stable chronic HFrEF. By shielding the heart from chronic sympathetic overdrive, beta-blockers reduce mortality. The caveat: start low, go slow, and never start them during acute decompensation.
4. "Digoxin prolongs survival, so it's a core drug." Digoxin improves symptoms and reduces hospitalisation but does not reduce mortality (the DIG trial). It is an adjunct, not a pillar — a common exam and clinical trap.
5. "More preload is always better because of Frank-Starling." Only up to the plateau. Beyond it, extra fluid buys no output and just floods the lungs. Over-transfusing or under-diuresing a failing heart is harmful.

Comparison and Connections

Concept	What it is	Key contrast
HFrEF vs HFpEF	Reduced vs preserved EF	Contraction problem vs relaxation problem
Preload vs afterload	Filling stretch vs ejection resistance	Diuretics target preload; vasodilators target afterload
Left vs right failure	Lung congestion vs systemic congestion	Orthopnoea/crackles vs raised JVP/oedema
Compensated vs decompensated	Stable on curve vs overwhelmed	Symptoms controlled vs acute pulmonary oedema
Digitalis vs neurohormonal drugs	Symptom/inotropy vs disease-modifying	Feel better vs live longer

Heart failure connects tightly to hypertension (the top cause of HFpEF and a major driver of HFrEF), ischaemic heart disease (the top cause of HFrEF), valvular disease, and atrial fibrillation (both cause and consequence). Its treatment rests on the physiology of the cardiac cycle and the RAAS in renal physiology.

Modern Treatment: The Four Pillars

For HFrEF, guideline therapy is now "quadruple therapy" — four drug classes, each proven to reduce mortality, started early and titrated together:

1. ARNI (sacubitril/valsartan) or ACE inhibitor — blocks RAAS, lowers afterload, reduces remodelling. ARNI (which also boosts protective natriuretic peptides) is superior (PARADIGM-HF).
2. Beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) — blocks chronic sympathetic toxicity.
3. MRA (mineralocorticoid receptor antagonist: spironolactone or eplerenone) — blocks aldosterone, reducing fibrosis and fluid retention.
4. SGLT2 inhibitor (dapagliflozin, empagliflozin) — the newest pillar, benefiting HFrEF and HFpEF, independent of diabetes.

Alongside these disease-modifiers, loop diuretics (furosemide) remain essential for symptom relief of congestion — but note they treat symptoms, not survival. Digoxin and hydralazine/nitrate combinations are adjuncts for selected patients. Notice how the whole regimen maps onto the physiology: three of four pillars break the neurohormonal cascade, and the fourth (SGLT2i) works partly through favourable effects on the kidney and metabolism.

Practice Questions

Recall

Q: What ejection fraction defines HFrEF, and what defines HFpEF? A: HFrEF: EF of 40% or below (impaired systolic contraction). HFpEF: EF of 50% or above (impaired diastolic filling). The 41–49% band is HFmrEF.

Understanding

Q: Why does a loop diuretic relieve a patient's breathlessness without necessarily improving cardiac output? A: In congestion the patient sits on the flat portion of a depressed Frank-Starling curve, where filling pressure is high but extra preload yields no extra stroke volume. Diuresis lowers preload and filling pressure, clearing pulmonary congestion (relieving dyspnoea), while stroke volume barely changes because output was preload-independent at that point on the curve.

Application

Q: A 68-year-old with hypertension, obesity, and atrial fibrillation is breathless with crackles and oedema, but echo shows EF 60%. What type of heart failure is this and which drug class has the best mortality evidence? A: HFpEF (preserved EF, stiff non-compliant ventricle). SGLT2 inhibitors are the class with the strongest mortality/hospitalisation evidence in HFpEF; diuretics relieve congestion, and comorbidities (BP, AF, weight) must be managed.

Analysis

Q: Beta-blockers reduce heart rate and contractility, both of which would seem to lower cardiac output. Explain why they nonetheless prolong survival in chronic HFrEF. A: Chronic sympathetic activation, though initially compensatory, causes myocyte death, arrhythmia, receptor downregulation, and adverse remodelling. Beta-blockers shield the myocardium from this chronic toxicity, slow the heart to improve diastolic filling and coronary perfusion, and reverse remodelling over months. The short-term drop in contractility is outweighed by long-term protection — which is why they must be started low and slow in stable, not acutely decompensated, patients.

FAQ

Is heart failure the same as a heart attack? No. A heart attack (myocardial infarction) is sudden death of heart muscle from a blocked coronary artery. Heart failure is a chronic syndrome of inadequate pumping — although a large heart attack is a leading cause of subsequent HFrEF.

Can heart failure be cured? Usually it is managed rather than cured. But it is far from hopeless: modern quadruple therapy can substantially improve symptoms, reverse some remodelling (recovering EF in some patients), and add years of life. Reversible causes (some valve disease, tachycardia-induced cardiomyopathy, alcohol) can improve markedly when treated.

Why do patients weigh themselves every day? Because rapid weight gain (about 2 kg over a few days) means fluid retention before it causes severe breathlessness. Catching it early allows a small diuretic adjustment at home and prevents a hospital admission.

Why is salt restricted? Sodium retention (driven by aldosterone) pulls water into the circulation, raising preload and worsening congestion. Limiting dietary salt reduces the fluid load the failing heart must handle.

Why isn't digoxin a first-line drug anymore if it was the original treatment? Digoxin relieves symptoms and reduces hospitalisation but does not extend life (DIG trial). The drugs that break the neurohormonal cascade — ACEi/ARNI, beta-blockers, MRAs, SGLT2i — do prolong survival, so they take priority; digoxin is now an adjunct.

What is BNP and why is it measured? B-type natriuretic peptide is a hormone released by ventricular muscle when it is stretched by high pressures. Elevated BNP/NT-proBNP supports a diagnosis of heart failure in a breathless patient, and a normal level makes it unlikely — a useful rule-out test.

Quick Revision

• Heart failure = heart cannot meet the body's demands at normal filling pressures; the heart is beating, not stopped.
• HFrEF (EF ≤40%): systolic/contraction failure, dilated ventricle, classically post-MI. HFpEF (EF ≥50%): diastolic/filling failure, stiff ventricle, hypertensive/obese/older patient.
• Preload = filling stretch; afterload = ejection resistance; contractility = intrinsic force.
• Frank-Starling: more stretch → stronger contraction, up to a plateau; the failing heart works on a low, flat curve. Congestion = pushed onto the flat top.
• Left failure → dyspnoea, orthopnoea, PND, crackles. Right failure → raised JVP, oedema, hepatomegaly.
• The neurohormonal cascade (sympathetic + RAAS) is compensatory then destructive; blocking it prolongs life.
• History: Withering's digitalis (1785) → diuretics (1950s–60s) → ACE inhibitors (CONSENSUS 1987) → beta-blockers (1990s) → the neurohormonal era.
• HFrEF quadruple therapy: ARNI/ACEi + beta-blocker + MRA + SGLT2 inhibitor; loop diuretic for symptoms. HFpEF: SGLT2 inhibitors + treat comorbidities.
• Digoxin improves symptoms but not survival.

Related Topics

Prerequisites

• Cardiology overview
• Cardiac cycle and the physiology of systole and diastole — see Physiology
• Renin-angiotensin-aldosterone system — see Physiology

Related Topics

• Hypertension and its role in HFpEF — see Cardiology
• Ischaemic heart disease and myocardial infarction — see Cardiology
• Cardiac pharmacology (diuretics, ACE inhibitors, beta-blockers) — see Pharmacology

Next Topics

• Cardiogenic shock and acute decompensated heart failure — see Critical Care Medicine
• Arrhythmias and atrial fibrillation — see Cardiology
• Valvular heart disease — see Cardiology